Tiger Pharmaceuticals (03347) announced interim results. Net loss attributable to company owners was approximately 413 million yuan year-on-year profit to loss

According to Zhitong Finance App, Tiger Pharmaceuticals (03347) announced its 2026 interim results, with revenue of 3,707.6 billion yuan, up 14.1% year on year; gross profit of about 1,021 billion yuan, up 4.3% year on year; net loss due to company owners about 413 million yuan, year-on-year profit and loss; shareholders of listed companies should account for net profit other than recurring profit and loss of about 278 million yuan, an increase of 31.8% year on year; loss per share.

According to the announcement, losses were mainly due to losses of 443 million yuan due to unrealized fair value changes, mainly financial instruments, and such losses are not taxable.